Bisphosphonate-Functionalized PLGA Nanocarriers for Doxorubicin Delivery to Primary Bone Tumors and Bone Metastases: From Mineral Affinity to Translational Evidence
Pharmaceutics · 29.10.2026 · 18 (11) · 1393
DOI: 10.3390/pharmaceutics18111393 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 29.10.2026. Verfasst von Pirscoveanu Denisa Floriana Vasilica und 8 weiteren Autor:innen. Die Arbeit nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Medicine and Pharmacy of Craiova.
Abstract (Originalsprache)
Poly(lactic-co-glycolic acid) (PLGA), doxorubicin, and bisphosphonates combine a biodegradable drug reservoir, a cytotoxic payload, and a mineral-binding ligand with potential antiresorptive activity. Their integration into a single nanocarrier, however, requires evidence of lesion-specific drug delivery and an improved therapeutic index. This structured critical narrative review evaluates the development and translational potential of bisphosphonate-functionalized PLGA nanocarriers for doxorubicin delivery to primary bone tumors and bone metastases. PubMed/MEDLINE, Scopus, and Web of Science were searched to identify formulation, mechanistic, preclinical, and clinically relevant evidence. The analysis distinguishes hydroxyapatite binding from lesion localization, nanoparticle uptake from intracellular availability of pharmacologically active doxorubicin, and skeletal protection from direct antitumor activity. Preclinical studies support the feasibility of alendronate- and zoledronate-modified carriers, but substantial differences in ligand chemistry, payload, architecture, disease models, and outcome measures prevent generalization of therapeutic superiority. Clinical evidence with bisphosphonates, including the negative OS2006 osteosarcoma trial, further cautions against extrapolating preclinical skeletal activity to clinical antitumor benefit. A staged translational framework is proposed linking product identity, biological stability, mineral interaction, drug-resolved biodistribution, intracellular exposure, comparative efficacy, safety, and reproducible manufacture. Future development should prioritize clearly defined disease settings and demonstration of a measurable exposure advantage over established therapeutic comparators.
Förderung
- University of Medicine and Pharmacy of Craiova
Zitieren
APA
Vasilica, P. D. F., Kamal, A. M., Trasca, D., Arsenie, C. C., Varut, R. M., Dorin, P. I., Rodica, D., Stoica, M., & Bogdan, N. (2026). Bisphosphonate-Functionalized PLGA Nanocarriers for Doxorubicin Delivery to Primary Bone Tumors and Bone Metastases: From Mineral Affinity to Translational Evidence. Pharmaceutics, 18(11), 1393. https://doi.org/10.3390/pharmaceutics18111393
Vancouver
Vasilica PDF, Kamal AM, Trasca D, Arsenie CC, Varut RM, Dorin PI, et al. Bisphosphonate-Functionalized PLGA Nanocarriers for Doxorubicin Delivery to Primary Bone Tumors and Bone Metastases: From Mineral Affinity to Translational Evidence. Pharmaceutics. 2026;18(11):1393. doi:10.3390/pharmaceutics18111393
BibTeX
@article{Vasilica2026,
author = {Vasilica, Pirscoveanu Denisa Floriana and Kamal, Adina Maria and Trasca, Diana-Maria and Arsenie, Cristian Cosmin and Varut, Renata Maria and Dorin, Pluta Ion and Rodica, Dirnu and Stoica, Maria and Bogdan, Niculescu},
title = {Bisphosphonate-Functionalized PLGA Nanocarriers for Doxorubicin Delivery to Primary Bone Tumors and Bone Metastases: From Mineral Affinity to Translational Evidence},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {11},
pages = {1393},
doi = {10.3390/pharmaceutics18111393}
}
EUVIMED